EGFR and non-small cell lung carcinoma: Recently at ASCO meeting 2021, the results of a randomized phase three trial, IMPACT, evaluating adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II–III NSCLC, were presented.